MDXG MiMedx

MiMedx Receives FTC Second Request for Sanara MedTech Merger

MiMedx and Sanara each received a Second Request from the FTC regarding the proposed merger. This extends the HSR waiting period until 30 days after substantial compliance with the request. The merger remains subject to HSR clearance and other closing conditions.

MiMedx Wins Court Ruling Vacating FDA's AXIOFILL Minimal Manipulation and Biologic Classification

Federal court vacated FDA's determinations that AXIOFILL is more than minimally manipulated and should be regulated as a biologic product. The matter is remanded to FDA for reconsideration using the correct tissue-characteristics standard relevant to recipient utility and with adequate explanation for any disparate treatment versus similar products.